A comparative study of various oxytocics in management of third stage of labour
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262126Keywords:
Postpartum haemorrhage, Carbetocin, Misoprostol, Uterotonic agentsAbstract
Background: Postpartum hemorrhage (PPH) is a leading cause of maternal mortality, with a global incidence of 2-11% following vaginal delivery. Active management of the third stage of labour (AMTSL) through prophylactic uterotonic administration is the cornerstone of PPH prevention. Comparative data on oxytocic agents from Indian tertiary care settings remain limited.
Methods: A prospective observational study was conducted at the Department of Obstetrics and Gynecology, Government Medical College, Akola, Maharashtra, from February 2024 to March 2026. A total of 224 women with uncomplicated term vaginal deliveries were allocated to five groups: Group A-Oxytocin 10 IU IM; group B-Misoprostol 600 µg sublingual; group C-Methylergometrine 0.2 mg IM; group D-Carboprost 250 µg IM; group E-Carbetocin 100 µg IV. Primary outcomes were duration of the third stage, haemoglobin (Hb) drop, and time to uterine tone. Secondary outcomes included side effects, blood transfusion requirement, and need for repeat dosing.
Results: Carbetocin demonstrated the shortest third stage (3.93 min), fastest uterine tone (1.86 min), lowest Hb drop (0.43 g/dL), no blood transfusions, lowest side effect rate (4.7%), and lowest repeat dose requirement (2.3%). Oxytocin and methylergometrine showed comparable efficacy. Misoprostol had the longest third stage (6.17 min), slowest uterine tone (8.47 min), and highest side effect rate (26.1%). Carboprost was effective but associated with a higher side effect burden (23.9%).
Conclusions: Carbetocin demonstrated superior efficacy and tolerability for AMTSL. Oxytocin remains the recommended first-line agent given its safety and cost profile. Misoprostol is viable in resource-limited settings despite its higher side effect rate.
References
Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams Obstetrics. 25th ed. New York: McGraw-Hill Education. 2018.
Borovac-Pinheiro A, Pacagnella RC, Cecatti JG, Miller S, El Ayadi AM, Souza JP, et al. Postpartum hemorrhage: new insights for definition and diagnosis. Am J Obstet Gynecol. 2018;219(2):162-8.
Ministry of Health and Family Welfare, Government of India. Maternal Health Division. Skills Lab Operational Guidelines: Training Manual. New Delhi: MoHFW. 2013.
World Health Organization. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: WHO. 2012.
Escobar MF, Nassar AH, Theron G, Eythan RB, Wanda N, Diana R, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet. 2022;157(1):3-50.
Rajan PV, Wing DA. Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. Clin Obstet Gynecol. 2010;53(1):165-81.
Federation of Obstetric and Gynaecological Societies of India (FOGSI). Guidance Note on Prevention and Management of Postpartum Hemorrhage. New Delhi: FOGSI. 2015.
Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;(4):CD005457.
Abd El Aziz MA, Iraqi A, Abedi P, Jahanfar S. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. Syst Rev. 2018;7(1):170.
Hofmeyr GJ, Walraven G, Gülmezoglu AM, Babalwa M, Zarko A, Jose V. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG. 2005;112(5):547-53.
Rahim AYHA, Ounsa MAAGE, Albarakati RG, Mohamed EY, Abdalla SM. Comparison between oxytocin, ergometrine and misoprostol in active management of the third stage of labour: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol. 2018;7:2076-80.
Wakhloo S, Dutta M, Bhat D, Sepolia N. Comparison study of various oxytocics in management of third stage of labour. Int J Life Sci Biotechnol Pharma Res. 2024;13(8):23-7.
Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev. 2000;(3):CD000007.
Mishra S, Tirkey S, Prasad A, Trivedi K. A comparative study of sublingual misoprostol versus intramuscular oxytocin in the active management of third stage of labor. Cureus. 2023;15(1):e33339.
Lalitha A. A comparative study to assess the efficacy and safety of oxytocin, misoprostol and carboprost in active management of third stage of labour at a tertiary care hospital. Int J Pharm Res Technol. 2025;15(2):734-7.
Downloads
Published
How to Cite
Issue
Section
